| Shareholder Rights Advocates at Levi & Korsinsky Investigate Lantheus Holdings, Inc. (LNTH) Regarding Possible Securities Fraud Violations |
NEW YORK, NY / ACCESS Newswire / May 16, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Lantheus Holdings, Inc. ("Lantheus Holdings, Inc.") (NASDAQ:LNTH) concerning possible violations of federal securities laws. On May 7, 2025, Lantheus reported its financial results for the first quarter of 2025. |
accessnewswire.com |
2025-05-16 11:30:00 |
Czytaj oryginał (ang.) |
| Lantheus Holdings, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - LNTH |
NEW YORK, NY / ACCESS Newswire / May 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Lantheus Holdings, Inc. ("Lantheus Holdings, Inc.") (NASDAQ:LNTH) concerning possible violations of federal securities laws. On May 7, 2025, Lantheus reported its financial results for the first quarter of 2025. |
accessnewswire.com |
2025-05-15 11:30:00 |
Czytaj oryginał (ang.) |
| Lantheus Holdings: Poor Results Caused By Temporary Problems - A Buy |
Lantheus shares fell 25% post-Q1 2025 report due to disappointing EPS guidance and not meet analysts' expectations. EPS reduction was driven by flat PYLARIFY sales and changes in Medicare coverage, impacting profitability and gross margins. Strategic transformation includes divesting the low-margin SPECT segment and acquiring LMI and Evergreen to expand into lucrative Alzheimer's and cancer diagnostics markets. |
seekingalpha.com |
2025-05-14 19:26:08 |
Czytaj oryginał (ang.) |
| Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn't Ignore |
Investors searching for high-quality opportunities in the pharmaceutical space should keep a close eye on stocks trading at extremely oversold levels. One of the most popular ways to measure this is through the Relative Strength Index (RSI), a technical momentum indicator that signals when a stock may be due for a rebound. |
marketbeat.com |
2025-05-14 12:30:32 |
Czytaj oryginał (ang.) |
| LNTH ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Lantheus Holdings, Inc. investment |
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Lantheus Holdings, Inc. ("Lantheus Holdings, Inc.") (NASDAQ:LNTH) concerning possible violations of federal securities laws. On May 7, 2025, Lantheus reported its financial results for the first quarter of 2025. |
accessnewswire.com |
2025-05-14 11:30:00 |
Czytaj oryginał (ang.) |
| Shareholders that lost money on Lantheus Holdings, Inc. (LNTH) should contact Levi & Korsinsky about Securities Fraud Investigation - LNTH |
NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Lantheus Holdings, Inc. ("Lantheus Holdings, Inc.") (NASDAQ:LNTH) concerning possible violations of federal securities laws. On May 7, 2025, Lantheus reported its financial results for the first quarter of 2025. |
accessnewswire.com |
2025-05-13 11:30:00 |
Czytaj oryginał (ang.) |
| Lantheus Holdings, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - LNTH |
NEW YORK, NY / ACCESS Newswire / May 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Lantheus Holdings, Inc. ("Lantheus Holdings, Inc.") (NASDAQ:LNTH) concerning possible violations of federal securities laws. On May 7, 2025, Lantheus reported its financial results for the first quarter of 2025. |
accessnewswire.com |
2025-05-12 11:30:00 |
Czytaj oryginał (ang.) |
| Shareholder Rights Advocates at Levi & Korsinsky Investigate Lantheus Holdings, Inc. (LNTH) Regarding Possible Securities Fraud Violations |
NEW YORK, NY / ACCESS Newswire / May 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Lantheus Holdings, Inc. ("Lantheus Holdings, Inc.") (NASDAQ:LNTH) concerning possible violations of federal securities laws. On May 7, 2025, Lantheus reported its financial results for the first quarter of 2025. |
accessnewswire.com |
2025-05-09 18:00:00 |
Czytaj oryginał (ang.) |
| Lantheus Holdings, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - LNTH |
LOS ANGELES , May 8, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Lantheus Holdings, Inc. ("Lantheus" or "the Company") (NASDAQ: LNTH) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. |
prnewswire.com |
2025-05-08 22:50:00 |
Czytaj oryginał (ang.) |
| Lantheus Holdings, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - LNTH |
LOS ANGELES--(BUSINESS WIRE)--Lantheus Holdings, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - LNTH. |
businesswire.com |
2025-05-07 21:26:00 |
Czytaj oryginał (ang.) |
| Lantheus Holdings, Inc. (LNTH) Q1 2025 Earnings Call Transcript |
Lantheus Holdings, Inc. (LNTH) Q1 2025 Earnings Call Transcript |
seekingalpha.com |
2025-05-07 15:23:18 |
Czytaj oryginał (ang.) |
| Lantheus Announces Sale of SPECT Business to SHINE Technologies |
Enables Lantheus to focus on innovative radiopharmaceuticals, while maximizing the value of its SPECT business SHINE will acquire products TechneLite®, NEUROLITE®, Xenon Xe-133 Gas, and Cardiolite® BEDFORD, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better patient outcomes, today announced a definitive agreement to sell its single photon emission computed tomography (SPECT) business to Illuminated Holdings, Inc., the parent company of SHINE Technologies, LLC (collectively, “SHINE”). |
globenewswire.com |
2025-05-06 20:01:00 |
Czytaj oryginał (ang.) |
| Lantheus Announces Alzheimer's Disease Radiodiagnostic MK-6240 Meets Co-Primary Endpoints in Two Pivotal Studies |
BEDFORD, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that its clinical-stage F18-labeled tau Positron Emission Tomography (PET) radiodiagnostic, MK-6240 (F18-florquinitau), successfully met its co-primary endpoints in two pivotal studies assessing its sensitivity and specificity. |
globenewswire.com |
2025-04-30 12:30:00 |
Czytaj oryginał (ang.) |
| Lantheus to Host First Quarter 2025 Earnings Conference Call and Webcast on May 7, 2025, at 8:00 a.m. Eastern Time |
BEDFORD, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, May 7, 2025, to discuss its financial and operating results for the first quarter of 2025. |
globenewswire.com |
2025-04-23 12:30:00 |
Czytaj oryginał (ang.) |
| Lantheus Completes Acquisition of Evergreen Theragnostics |
BEDFORD, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that it has completed its previously announced acquisition of Evergreen Theragnostics, Inc. (“Evergreen”), a clinical-stage radiopharmaceutical company. The acquisition was first announced on January 28, 2025. |
globenewswire.com |
2025-04-01 13:00:00 |
Czytaj oryginał (ang.) |
| Lantheus Holdings: Pylarify Makes Bull Case Despite Looming Patent Expiry |
Lantheus Holdings, Inc.'s stock has surged 55% since my last “Buy” rating, driven by strong revenue growth from Pylarify and Definity, and a profitable business model. Strategic acquisitions, including Life Molecular Imaging and Evergreen Theragnostics, have diversified Lantheus' pipeline, targeting new markets like Alzheimer's diagnostics and oncology therapeutics. Pylarify's potential patent expiration in 2026 poses a risk, but management is actively seeking to extend protections and diversify revenue streams. |
seekingalpha.com |
2025-03-07 13:12:21 |
Czytaj oryginał (ang.) |
| Lantheus' Pylarify Hit $1B in 2024 Sales |
Lantheus Holdings (LNTH -1.07%) held its fourth-quarter and full-year 2024 earnings call on Feb. 26, 2025, highlighting achievements in its radiopharmaceutical portfolio and announcing strategic transactions. |
fool.com |
2025-02-27 13:02:28 |
Czytaj oryginał (ang.) |
| Lantheus Holdings, Inc. (LNTH) Q4 2024 Earnings Call Transcript |
Lantheus Holdings, Inc. (NASDAQ:LNTH ) Q4 2024 - Earnings Conference Call February 26, 2025 8:00 AM ET Company Participants Mark Kinarney - VP of IR Brian Markison - CEO Paul Blanchfield - President Bob Marshall - CFO Amanda Morgan - Chief Commercial Officer Conference Call Participants Roanna Ruiz - Leerink Partners Anthony Petrone - Mizuho Financial Group Richard Newitter - Truist Securities Paul Choi - Goldman Sachs Matt Taylor - Jefferies Yuan Zhi - B. Riley Larry Solow - CJS Securities Justin Walsh - Jones Trading Andy Hsieh - William Blair John Vandermosten - Zacks Kemp Dolliver - Brookline Capital Markets David Turkaly - Citizens JMP Operator Good morning. |
seekingalpha.com |
2025-02-26 12:49:28 |
Czytaj oryginał (ang.) |
| Lantheus (LNTH): A 10x Opportunity in Radiopharmaceuticals |
Explore the exciting world of Lantheus Holdings (LNTH 1.39%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! |
fool.com |
2025-02-25 21:00:00 |
Czytaj oryginał (ang.) |
| Lantheus Appoints Phuong Khanh (P.K.) Morrow, M.D. |
BEDFORD, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Phuong Khanh (P.K.) Morrow, M.D. to Lantheus' Board of Directors (“Board”), effective February 1, 2025. Dr. Morrow is an experienced pharmaceutical executive and physician-scientist with deep expertise leading end-to-end clinical development in the field of oncology. As an independent director, Dr. Morrow will serve as a member of the Board's Science and Technology Committee, where her proven track record in advancing clinical programs and wealth of knowledge in oncology therapeutics development will help guide the success of Lantheus' strategic initiatives and innovation efforts. Following her appointment, the Board will be comprised of eleven directors, nine of whom are independent. |
globenewswire.com |
2025-01-30 10:30:00 |
Czytaj oryginał (ang.) |
| Why Lantheus Holdings Stock Got Thrashed on Tuesday |
Radiopharmaceutical specialist Lantheus Holdings (LNTH -7.30%) had some news to report Tuesday morning, but the market didn't greet it warmly. Following its announcement of a fresh acquisition, investors traded out of the niche healthcare stock, leaving it with a more than 7% loss on the day. |
fool.com |
2025-01-29 06:30:04 |
Czytaj oryginał (ang.) |
| Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader |
Advances radiopharmaceutical leadership with addition of scalable manufacturing infrastructure and end-to-end clinical development capabilities Adds OCTEVY™, a registrational-stage diagnostic asset, targeting neuroendocrine tumors that is complementary to Lantheus' therapeutic agent , PNT2003 Expands oncology radiopharmaceutical pipeline with multiple clinical and pre-clinical theranostic pairs Company reaffirms Full-Year and Fourth Quarter, 2024 financial guidance Company to host conference call on January 28, 2025, at 8:30 AM ET BEDFORD, Mass. , Jan. 28, 2025 /PRNewswire/ -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced a definitive agreement to acquire Evergreen Theragnostics, Inc. ("Evergreen"), in an all-cash transaction consisting of an upfront payment of $250 million and up to an additional $752.5 million in potential milestone payments. |
prnewswire.com |
2025-01-28 08:30:00 |
Czytaj oryginał (ang.) |
| Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader |
Advances radiopharmaceutical leadership with addition of scalable manufacturing infrastructure and end-to-end clinical development capabilities |
globenewswire.com |
2025-01-28 08:00:00 |
Czytaj oryginał (ang.) |
| Lantheus to Acquire Life Molecular Imaging for an Upfront Payment of $350 Million to Accelerate Innovation for Patients in the Growing Alzheimer's Disease Radiodiagnostic Market |
Enhances Lantheus' growth profile with Neuraceq®, a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimer's Disease |
globenewswire.com |
2025-01-13 02:05:00 |
Czytaj oryginał (ang.) |
| Lantheus Holdings: Powerhouse Potential In 2025 |
Lantheus Holdings is a strong buy due to its dominant market position and promising growth prospects in radiopharmaceuticals and Alzheimer's diagnostics. PYLARIFY, Lantheus' top revenue generator, is projected to reach $2.5 billion by 2030, driven by its superior PSMA PET imaging technology. DEFINITY holds an 80% market share in ultrasound imaging, with the market expected to nearly double, further solidifying Lantheus' financial stability. |
seekingalpha.com |
2025-01-01 21:43:48 |
Czytaj oryginał (ang.) |
| Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia |
SYDNEY, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that it has entered into a strategic co-development partnership with Lantheus to advance the clinical development of innovative radiopharmaceuticals in Australia. |
globenewswire.com |
2024-12-30 10:00:00 |
Czytaj oryginał (ang.) |
| 2 Stock Market Predictions for 2025: 2 Stocks Worth Buying No Matter What Happens |
In this video, Motley Fool contributors Jason Hall and Tyler Crowe make two predictions about the market in 2025, and also share two stock picks they think will do well no matter what happens with the market this year: Lantheus (LNTH -1.26%) and Synopsys (SNPS -0.99%). |
fool.com |
2024-12-30 09:14:30 |
Czytaj oryginał (ang.) |
| Lantheus Holdings: A Growing Business With Dominant Market Share |
Lantheus Holdings (LNTH) is a profitable company with strong products like PYLARIFY and DEFINITY, both showing double-digit growth and dominant market share. Management has demonstrated excellent execution, particularly with PYLARIFY, which is on track to exceed $1 billion in sales by Q4 2024. The company is financially robust, with nearly $1 billion in cash, minimal debt, and strong operating cash flow, positioning it well for acquisitions. |
seekingalpha.com |
2024-12-12 16:01:29 |
Czytaj oryginał (ang.) |
| Why Lantheus Holdings Stock Won Big on Wednesday |
Why Lantheus Holdings Stock Won Big on Wednesday |
fool.com |
2024-11-20 20:54:18 |
Czytaj oryginał (ang.) |
| Lantheus Announces Share Repurchase Program |
BEDFORD, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announces that its board of directors has authorized a program to repurchase up to $250 million of its common stock during the next twelve months. |
globenewswire.com |
2024-11-20 03:00:00 |
Czytaj oryginał (ang.) |
| Lantheus to Present at the Jefferies London Healthcare Conference |
BEDFORD, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Bob Marshall, Chief Financial Officer and Treasurer, will present at the Jefferies London Healthcare Conference at 1:00 p.m. GMT (8 a.m. EST) on Wednesday, November 20. |
globenewswire.com |
2024-11-13 10:30:00 |
Czytaj oryginał (ang.) |
| Lantheus Continues to Commend CMS' CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals and Reaffirms Outlook for PYLARIFY's Blockbuster Status for 2025 |
BEDFORD, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, notes that the Centers for Medicare & Medicaid Services (CMS) recently posted updated payment rates in Addendum B related to the final rule for the calendar year 2025 Medicare Hospital Outpatient Prospective Payment System (OPPS). The Company continues to commend CMS for recognizing the value of and ensuring broad patient access to specialized diagnostic radiopharmaceuticals. With PYLARIFY® (piflufolastat F 18) on track to exceed $1 billion in sales in 2024, Lantheus reaffirms its 2025 outlook for PYLARIFY as a blockbuster brand that will continue to be the clear standard and #1 ordered PSMA PET imaging agent in the U.S. |
globenewswire.com |
2024-11-11 09:39:00 |
Czytaj oryginał (ang.) |
| Lantheus Holdings: Q3 Results Were Good But Market Overreacted |
Lantheus, with a strong pharmaceutical portfolio and double-digit growth, fell 20% post-Q3 2024 due to expected weak Q4 EPS from temporary expenses. Key products Pylarify and Definity enhance diagnostic imaging for prostate cancer and heart conditions, respectively, with significant market potential and government support. Despite a conservative Q4 outlook, Lantheus' forward P/E of 13 and projected 15% annual revenue growth present an attractive buying opportunity. |
seekingalpha.com |
2024-11-08 12:06:36 |
Czytaj oryginał (ang.) |
| Lantheus Holdings, Inc. (LNTH) Q3 2024 Earnings Call Transcript |
Lantheus Holdings, Inc. (NASDAQ:LNTH ) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ET Company Participants Mark Kinarney - VP of IR Brian Markison - CEO Paul Blanchfield - President Bob Marshall - CFO Jeff Humphrey - Chief Medical Officer Conference Call Participants Roanna Ruiz - Leerink Partners Anthony Petrone - Mizuho Group Richard Newitter - Truist Securities Matt Taylor - Jefferies Larry Solow - CJS Securities Tara Bancroft - TD Cowen Yuan Zhi - B. Riley Kemp Dolliver - Brookline Capital Markets Justin Walsh - Jones Trading Andy Hsieh - William Blair Ed Ridley-Day - Redburn Atlantic Operator Good morning. |
seekingalpha.com |
2024-11-06 13:27:09 |
Czytaj oryginał (ang.) |
| Lantheus Applauds CMS' CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals, Advancing Patient Access and Care |
BEDFORD, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, applauds the Centers for Medicare & Medicaid Services' (CMS) final rule for the calendar year 2025 Medicare Hospital Outpatient Prospective Payment System (OPPS). The rule, announced and detailed on the CMS website late Friday, recognizes the value of and ensures broad patient access to specialized diagnostic radiopharmaceuticals by improving the accuracy of payment amounts for these products. |
globenewswire.com |
2024-11-04 09:30:00 |
Czytaj oryginał (ang.) |
| Lantheus to Host Third Quarter 2024 Earnings Conference Call and Webcast on November 6, 2024, at 8:00 a.m. Eastern Time |
BEDFORD, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, November 6, 2024, to discuss its financial and operating results for the third quarter of 2024. |
globenewswire.com |
2024-10-23 12:30:00 |
Czytaj oryginał (ang.) |
| Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024 |
Study met its primary endpoint, demonstrating significant improvement in radiographic progression-free survival Overall Response Rate was 38.1% vs. 12.0% for the ARPI switch arm, including 9.3% Complete Responses Patients demonstrated statistically significant improvement in time to reduction of health-related quality of life (HRQoL) as measured by Functional Assessment of Cancer Therapy—Prostate (FACT-P) Interim Overall Survival Crossover Adjusted Hazard Ratio was |
globenewswire.com |
2024-09-15 12:45:00 |
Czytaj oryginał (ang.) |
| Lantheus Appoints Julie Eastland as New Board Member |
BEDFORD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Julie Eastland, an experienced biotechnology and financial executive, to Lantheus' Board of Directors (“Board”), effective as of September 3, 2024. As an independent director, Ms. Eastland will serve as a member of the Board's Audit Committee. Following the appointment of Ms. Eastland, the Board will be comprised of ten directors, eight of whom are independent. |
globenewswire.com |
2024-09-05 12:30:00 |
Czytaj oryginał (ang.) |
| Lantheus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference |
BEDFORD, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Brian Markison, Chief Executive Officer, will present at the Morgan Stanley 22nd Annual Global Healthcare Conference at 7:45 a.m. ET on Wednesday, September 4. |
globenewswire.com |
2024-08-28 12:30:00 |
Czytaj oryginał (ang.) |
| Lantheus: A Radiopharmaceutical Powerhouse In The Making (Q2 2024 Update) |
PYLARIFY is the leading PSMA PET imaging agent, on track to surpass $1 billion in sales by 2024, driving significant revenue growth for Lantheus Holdings, Inc. Lantheus is heavily investing in its oncology and Alzheimer's diagnostics pipeline, positioning itself for substantial long-term growth despite short-term profit impacts. With robust free cash flow, a solid balance sheet, and potential for significant EPS growth, Lantheus Holdings is undervalued and could reach $250 per share by 2028. |
seekingalpha.com |
2024-08-12 19:32:51 |
Czytaj oryginał (ang.) |
| 13 stocks to consider if you're able to brave recession fears |
Now that stock investors are beginning to realize that a recession isn't on the way, the U.S. market will get back to doing what is up to before the August swoon: showing strength beyond the Magnificent Seven. |
marketwatch.com |
2024-08-12 11:15:00 |
Czytaj oryginał (ang.) |
| Lantheus Reports Second Quarter 2024 Financial Results |
Second Quarter 2024 Worldwide revenue of $394.1 million, an increase of 22.5% from second quarter 2023 Completed three strategic transactions to expand innovative pipeline GAAP fully diluted earnings per share of $0.88, compared to $1.33 in second quarter 2023. Adjusted fully diluted earnings per share of $1.80 compared to $1.54 in the second quarter 2023, reflective of inter-quarter investment in business development and R&D. |
globenewswire.com |
2024-07-31 11:00:00 |
Czytaj oryginał (ang.) |
| Lantheus to Host Second Quarter 2024 Earnings Conference Call and Webcast on July 31, 2024, at 8:00 a.m. Eastern Time |
BEDFORD, Mass., July 17, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, |
globenewswire.com |
2024-07-17 12:30:00 |
Czytaj oryginał (ang.) |
| Lantheus Acquires NAV-4694, a Next-Generation ß Amyloid PET Imaging Agent for Alzheimer's Disease |
Acquisition Expands Pipeline and Strengthens Alzheimer's Diagnostic Capabilities Acquisition Expands Pipeline and Strengthens Alzheimer's Diagnostic Capabilities |
globenewswire.com |
2024-07-15 12:30:00 |
Czytaj oryginał (ang.) |